View in EDS PDF Full Text

Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies?

Saved in:
Bibliographic Details
Title: Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies?
Authors: Janardhan SV; Center for Liver Diseases, Section of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Chicago, Chicago, IL, USA., Reau NS; Center for Liver Diseases, Section of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Chicago, Chicago, IL, USA.
Source: Hepatic medicine : evidence and research [Hepat Med] 2015 Apr 16; Vol. 7, pp. 11-20. Date of Electronic Publication: 2015 Apr 16 (Print Publication: 2015).
Publication Type: Journal Article; Review
Journal Info: Publisher: Dove Medical Press Country of Publication: New Zealand NLM ID: 101544801 Publication Model: eCollection Cited Medium: Print ISSN: 1179-1535 (Print) Linking ISSN: 11791535 NLM ISO Abbreviation: Hepat Med Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 25926761
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies?
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Janardhan+SV%22">Janardhan SV</searchLink>; Center for Liver Diseases, Section of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Chicago, Chicago, IL, USA.<br /><searchLink fieldCode="AU" term="%22Reau+NS%22">Reau NS</searchLink>; Center for Liver Diseases, Section of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Chicago, Chicago, IL, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101544801%22">Hepatic medicine : evidence and research</searchLink> [Hepat Med] 2015 Apr 16; Vol. 7, pp. 11-20. <i>Date of Electronic Publication: </i>2015 Apr 16 (<i>Print Publication: </i>2015).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Review
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Dove+Medical+Press%22">Dove Medical Press </searchLink><i>Country of Publication: </i>New Zealand <i>NLM ID: </i>101544801 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>1179-1535 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2211791535%22">11791535 </searchLink><i>NLM ISO Abbreviation: </i>Hepat Med <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=25926761
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.2147/HMER.S79584
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 11
    Titles:
      – TitleFull: Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies?
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Janardhan SV
      – PersonEntity:
          Name:
            NameFull: Reau NS
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 16
              M: 04
              Text: 2015 Apr 16
              Type: published
              Y: 2015
          Identifiers:
            – Type: issn-print
              Value: 1179-1535
          Numbering:
            – Type: volume
              Value: 7
          Titles:
            – TitleFull: Hepatic medicine : evidence and research
              Type: main
ResultId 1